Horizon Europe’s partnership for antimicrobial resistance (AMR) research was launched last week, marking a significant step towards bringing Europe closer to discovering new antimicrobial therapies within the next decade.

With a stronger emphasis on innovation compared to its Horizon 2020 predecessor, this partnership aims to accelerate the development of potential therapies and move them closer to the market.

The ten-year initiative pools €253 million in research funding from 30 countries, including €75 million contributed by Horizon Europe.

The partnership’s first call, which will focus on treatments, is scheduled to launch in November with a budget of approximately €35 million. While the official call text has not yet been published, a pre-announcement is expected in mid-October.

Treatment is one of three key focus areas highlighted by the partnership, underscoring its commitment to tackling antimicrobial resistance through targeted research and innovation.
https://sciencebusiness.net/news/r-d-funding/antimicrobial-resistance/horizon-europes-new-antimicrobial-resistance-partnership-looks